Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
CLRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.11 - $67.50
Previous CloseN/A
Volume1.30M
Average Volume (3M)136.10K
Market Cap
$15.90M
Enterprise Value$2.75M
Total Cash (Recent Filing)$11.04M
Total Debt (Recent Filing)$453.51K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Oct 30, 2025EPS Estimate
-2.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.39
Shares Outstanding3,192,040
10 Day Avg. Volume102,733
30 Day Avg. Volume136,098
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$15.20Price Target Upside205.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalCellectar recently held a meeting with the FDA, which confirmed a clear path to accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia.
Strategic PartnershipsCellectar remains in active discussions with potential partners to out-license Iopofosine-131 in Waldenstrom’s macroglobulinemia (WM).
Bears Say
Financial PerformanceCellectar reported 2Q25 results with a net loss of ($5.4M) and ended the period with $11.0M in cash.
Program Development UncertaintyCellectar's radiopharma pipeline, including the P1-ready assets CLR-121225 and CLR-121125, were the key drivers for CLRB. As the company now seeks strategic alternatives for its assets, there is significant uncertainty regarding the future development of these programs.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $4.11 and its highest was $67.50 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $15.90M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Oct 30, 2025 which is in 51 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Aug 14, 2025. The company reported -$3.39 earnings per share for the quarter, beating the consensus estimate of -$3.719 by $0.329.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -2.53.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 3,192,040 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$3.39 in its last earnings report, beating expectations of -$3.719. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
Cellectar Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.20 (205.22% Upside)
$15.20 (205.22% Upside)
Blogger Sentiment
Bullish
CLRB Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $124.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.09%
12-Months-Change
Fundamentals
Return on Equity
-273.88%
Trailing 12-Months
Asset Growth
-53.39%
Trailing 12-Months
Company Description
Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in regulatory strategies and product pipeline advancements, especially with the potential accelerated approval path for Iopofosine I-131. However, the notable decrease in R&D and administrative expenses and an increased net loss indicate financial challenges. Overall, the sentiment is cautiously optimistic but tempered by financial concerns.View all CLRB earnings summariesCLRB Stock 12 Month Forecast
Average Price Target
$15.20
▲(205.22% Upside)
Technical Analysis
Can-Fite BioPharma
―
Minerva Neurosciences
―
AlphaTON Capital
―
Leap Therapeutics
―
Equillium
―
Ownership Overview
12.03% Insiders
4.34% Mutual Funds
1.04% Other Institutional Investors
78.87% Public Companies and
Individual Investors